This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a multi-centre, double blind, randomised controlled trial. Subjects were stratified on the basis of strategic or perennial allergy and they were randomly assigned to each of the three treatment groups using a computer program. The duration of follow-up was 16 weeks following commencement of treatment. 18 patients (32%) were lost to follow-up, 9 patients chose to discontinue treatment, 6 did not appear for follow up, one patient violated the treatment protocol and two were withdrawn because of a lack of treatment efficacy.
Analysis of effectiveness
The analysis of effectiveness was based on intention to treat. The primary health outcomes used were the number of asthmatic symptoms reported and peak flow measurements. The authors stated that there were no important differences in baseline clinical characteristics or demographic information for subjects in the three groups.
Effectiveness results
There was a statistically significant improvement in peak expiratory flow performance rates for patients receiving budesonide compared with those in the placebo group both before and after taking treatment in the morning and evening, (p<=0.05). The number of symptoms reported by patients was also significantly lower in the intervention groups compared with the placebo group by the end of 8 weeks for early morning symptoms (p<0.01) and 12 weeks for nocturnal symptoms, (p<0.001). Furthermore, more patients reported a reduced impact of asthma in the intervention groups than in the placebo group, (p=0.01).
Clinical conclusions
The results of the study suggest that the use of low dosages of corticosteroids for patients with mild asthma can be effective in disease management and treatment without causing any undue adverse events.
Measure of benefits used in the economic analysis
Monetary benefits. Benefits were estimated using a willingness to pay questionnaire completed upon entry and completion of the study. Initially subjects were asked to state how much they were willing to pay to avoid asthma and associated problems. At the end of the study patients were asked whether the impact of asthma was less, and their willingness to pay to continue with treatment for improved outcomes where appropriate.
Direct costs
The cost of drug therapy, use of bronchodilators and other health care services were estimated. Costs of drug therapy were taken from the Ontario Ministry of Health. The costs of hospital services were estimated using a local Ontario hospital costing model and similarly physicians' fees were determined using the Ontario Hospital Insurance Programme. Quantities of resources used were observed during the study period. The price years used in the model were not stated. Discounting was not used: this was appropriate given the short duration of the intervention. Costs were determined from the perspective of a third party payer. The cost of drug dispensing was assumed to be the same for all groups and therefore were not included in the analysis.
Further well designed economic evaluations conducted alongside clinical trials of different populations, including children, are required to further test the conclusions reached in this study. Attempts should be made to recruit a larger patient sample, and lower dosages of corticosteroid treatment may also be worth evaluating. Mechanisms to improve patient compliance with treatment may also be worth including in further analysis, given the high dropout rate in this study. Longer term trials are required to assess any adverse events and risks associated with use of inhaled corticosteroids.
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